Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation: A meta analysis of adjusted analysis in routine practice settings

Darwiche, Walid; Bejan-Angoulvant, Théodora; Diévart, François; Babuty, Dominique; Angoulvant, Denis; Fauchier, Laurent

doi:10.1016/j.ijcard.2016.01.065

Cited by 3 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Major bleeding did not happen in our sample. Our results are consistent with a recent meta-analysis that showed that dabigatran etexilate use is not associated with bleeding issues in atrial fibrillation patients 12 . However, interruption due to cost was very significant in our sample, with 22% of patients changing treatment.…”

Section: Discussionsupporting

confidence: 93%

Dabigatran and warfarin in nonvalvular atrial fibrillation or atrial flutter in outpatient clinic practice in Brazil

Monteiro

San-Martin

Silva

et al. 2019

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Objectives: To compare warfarin and dabigatran for thromboembolic event prevention in patients with nonvalvular atrial fibrillation or atrial flutter. Methods: This was a retrospective cohort of participants with nonvalvular atrial fibrillation or atrial flutter using either warfarin or dabigatran in a reference center in Brazil. Results: There were 112 patients (mean age 65.5 years), with 55.3% using warfarin. The median duration of follow-up was 1.9 years for warfarin and 1.6 years for dabigatran (p = 0.167). Warfarin patients had a higher median of medical appointments per year (8.3 [6.8-10.4] vs 3.1 [2.3-4.2], p < 0.001) and the frequency of minor bleeding was more than four times higher (17.7% vs 4.0%, p = 0.035). Among patients with prior stroke, those using warfarin had 2.6 times more medical appointments for person-years of follow-up (8.5 vs 3.3). There was no major bleeding or embolic event during follow-up period. Conclusion: The dabigatran group had a lower frequency of minor bleeding and number of medical appointments than the warfarin group, without more embolic events or major bleeding.

show abstract

Section: Discussionsupporting

confidence: 93%